Publications by authors named "K R Glenn"
COVID-19 outbreak and genomic investigation in an inpatient behavioral health unit.
Antimicrob Steward Healthc Epidemiol
April 2024
Article Synopsis
- - The study focused on identifying how COVID-19 spread in an inpatient behavioral health unit (BHU) during the Omicron surge, noting the unique challenges of social interaction in these settings.
- - Investigators found multiple transmission routes, discovering 35 healthcare workers and 8 inpatients tested positive, with origins traced to both staff and visitors.
- - An effective outbreak control plan was implemented, which included increased personal protective measures and limited socialization, helping to reduce further transmission while minimizing disruptions to care.
Introduction: Inhalation injury is a major risk factor for mortality in burn patients via 3 primary mechanisms: airway edema and obstruction, hypoxemic respiratory failure, and pneumonia. Currently, the mainstay of treatment is supportive care to include early intubation, lung-protective or high-frequency-percussive mechanical ventilation, nebulized heparin, and aggressive pulmonary toilet. Despite these treatments, a subset of these patients progress to severe acute respiratory distress syndrome (ARDS) for which rescue options are limited.
View Article and Find Full Text PDFDistribution, Metabolism, and Excretion of Cenobamate in Adult, Fetal, Neonatal, and Lactating Rats.
Eur J Drug Metab Pharmacokinet
January 2024
Background And Objective: Cenobamate is an antiseizure medication (ASM) approved for treatment of focal epilepsy in adults. The objective of this study was to characterize the distribution, metabolism, and excretion of cenobamate in adult and pre- and postnatal rats, including pregnant and lactating females and nursing pups.
Methods: Distribution, metabolic, and excretion profiles were determined for C-labeled and unlabeled cenobamate using liquid scintillation counting, radiochromatography, LCMS, and LCMS/MS after oral or intravenous (IV) administration.
Background: Cenobamate is an antiseizure medication used to treat partial-onset (focal) seizures. It is a molecule with one chiral center and a unique dual mechanism of action: enhancement of fast and slow inactivation of sodium channels with preferential inhibition of the persistent current and positive allosteric modulation of GABA receptor-mediated ion channels.
Aims/methods: Anticonvulsant effects of cenobamate (YKP3089; R-enantiomer), YKP3090 (S-enantiomer), and YKP1983 (racemate) were evaluated in chemically and electrically induced focal and generalized seizure models in rodents.